Physician profile
James Keith Chafin
NPI 1255392452
$472.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.41 | 2019 | |
| Minerva Surgical, INC | $83.35 | 2019 | |
| Pfizer INC. | $37.45 | 2019 | |
| Astellas Pharma US INC | $31.96 | 2019 | |
| Therapeuticsmd, INC. | $22.40 | 2019 | |
| Duchesnay USA Incorporated | $19.89 | 2019 | |
| Daiichi Sankyo INC. | $16.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.46 | 2019 | |
| Lupin INC. | $12.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.55 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.27 | 2019 | |
| Avion Pharmaceuticals | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chafin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.